Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer

At present, no cell drug with an indication for mCRPC has been approved for marketing in China, and there is no scholar to fight against it PSMA-CAR-NK cell therapy CRPC was reported in a study. Based on the previous basic research, our company has developed CAR-NK cell injection, hoping to further evaluate its safety, tolerability and preliminary efficacy in the treatment of mCRPC patients in clinical studies, and provide new possibilities for the selection of clinical treatment strategies

Trial Details

NCT ID

NCT07156045

Phase

EARLY_PHASE1

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Status

RECRUITING

Cancer Type

Castration-Resistant (CRPC) Prostate Cancer

Interventions

anti-PSMA CAR-NK

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

To enter the trial, subjects had to meet all of the following eligibility criteria:
diagnosed metastatic castration-resistant prostate cancer (mCRPC);
Castration level of serum testosterone (\< 50 ng/dL or \< 1.7 nmol/L);
Positive expression of PSMA;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →